Progesterone Vaginal Gel
- Package NDC
- 0023-6150-04
- Manufacturer
- AbbVie Inc.
- Product / route
- CRINONE / VAGINAL
- FDA record status
- To Be Discontinued
- Reported availability
- Unknown
- FDA reason
- Not supplied
- FDA record updated
- 03/27/2026
Progesterone
Regulatory registry
- Context
- FDA-approved product context
- Reason / limits
- Oral progesterone capsules have defined endometrial-hyperplasia prevention and amenorrhea uses.
- Last source review
- October 10, 2026
- Review scope
- Earlier editorial source context. Not a new medical or regulatory review.
- Clinical phase
- Unknown: no current trial-specific phase check is included in this registry.
- Registry NDC / manufacturer
- Unknown unless linked to a matched FDA package record below.
Research-only means this library makes no approved-treatment claim. Compounding context does not mean compounded-only, authorized for compounding, or legally available. Product-specific source limits control.
Regulatory sources
FDA shortage tracker
Approval context and shortage status are separate. An NDC identifies a package; it does not establish FDA approval or permission to compound.
Discontinuation / mixed recordsMatched records include discontinuation notices or mixed non-current states. Check each package; no compound-wide stock conclusion is made.
Full dated shortage record · All compound tracker entries
Matched package records (1)
Records match a single exact active substance. Route and presentation are shown separately; a record does not apply to every product or preparation.
Observed change history (1)
Observed dates are when our sync saw a source state, not when a shortage started or ended. Unchanged daily checks do not add duplicate events.
Discontinuation / mixed records
Observed Oct 16, 2026, 11:34 AM CDT. FDA dataset 2026-10-16.
Previous observed state: Unknown.